Subscribe Us

header ads

Recents

header ads

Artificial Intelligence (AI) in Oncology Market Size, Growth, Demands Outlook and Forecasts to 2032

Precedence Research - February 27, 2023

According to the research report, the global artificial intelligence (AI) in oncology market size is expected to touch USD 10,680.29 Million by 2032, from USD 891.44 Million in 2022, growing with a significant CAGR of 28.18% from 2023 to 2032. 

Artificial Intelligence (AI) in Oncology Market Size 2023 To 2032

The artificial intelligence (AI) in oncology report offers a comprehensive study of the current state expected at the major drivers, market strategies, and key vendors’ growth. The report presents energetic visions to conclude and study the market size, market hopes, and competitive surroundings. The research also focuses on the important achievements of the market, research & development, and regional growth of the leading competitors operating in the market. The current trends of the global artificial intelligence (AI) in oncology in conjunction with the geographical landscape of this vertical have also been included in this report.

The report offers intricate dynamics about different aspects of the global artificial intelligence (AI) in oncology market, which aids companies operating in the market in making strategic development decisions. The study also elaborates on significant changes that are highly anticipated to configure growth of the global artificial intelligence (AI) in oncology during the forecast period. It also includes a key indicator assessment that highlights growth prospects of this market and estimates statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).

Sample Link @ https://www.precedenceresearch.com/sample/2638

 Report Scope of the Artificial Intelligence (AI) in Oncology Market

Report CoverageDetails
Market Size in 2023USD 1,142.72 Million
Market Size by 2032USD 10,680.29 Million 
Growth Rate from 2023 to 2032CAGR of 28.18%
Largest MarketNorth America
Base Year2022
Forecast Period2023 to 2032
Segments CoveredBy Component, By Cancer Type, By Treatment Type and By End-Users
Regions CoveredNorth America, Europe, Asia-Pacific, Latin America and Middle East & Africa

This study covers a detailed segmentation of the global artificial intelligence (AI) in oncology market, along with key information and a competition outlook. The report mentions company profiles of players that are currently dominating the global artificial intelligence (AI) in oncology market, wherein various developments, expansions, and winning strategies practiced and implemented by leading players have been presented in detail.

Key Players

  • IBM
  • Azra AI
  • Siemens Healthineers
  • GE Healthcare
  • Intel
  • Path AI
  • NVIDIA
  • Concert.AI
  • Digital Diagnostics Inc.
  • Median Technologies

Market Segmentation

 By Component

  • Software Solutions
  • Hardware
  • Services

By Cancer Type

  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Brain Tumor
  • Others

By Treatment Type

  • Chemotherapy
  • Radiotherapy
  • Immunotherapy
  • Others

By End-Users

  • Hospitals
  • Diagnostic Centers
  • Pharmaceutical Companies
  • Research Institutes
  • Others

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • The Middle East and Africa

Research Methodology

The research methodology adopted by analysts for compiling the global artificial intelligence (AI) in oncology report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.

During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.

For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global artificial intelligence (AI) in oncology market.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Artificial Intelligence (AI) in Oncology Market 

5.1. COVID-19 Landscape: Artificial Intelligence (AI) in Oncology Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Artificial Intelligence (AI) in Oncology Market, By Component

8.1. Artificial Intelligence (AI) in Oncology Market, by Component, 2023-2032

8.1.1. Software Solutions

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Hardware

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. Services

8.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Artificial Intelligence (AI) in Oncology Market, By Cancer Type

9.1. Artificial Intelligence (AI) in Oncology Market, by Cancer Type, 2023-2032

9.1.1. Breast Cancer

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Lung Cancer

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Prostate Cancer

9.1.3.1. Market Revenue and Forecast (2020-2032)

9.1.4. Colorectal Cancer

9.1.4.1. Market Revenue and Forecast (2020-2032)

9.1.5. Brain Tumor

9.1.5.1. Market Revenue and Forecast (2020-2032)

9.1.6. Others

9.1.6.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Artificial Intelligence (AI) in Oncology Market, By Treatment Type 

10.1. Artificial Intelligence (AI) in Oncology Market, by Treatment Type, 2023-2032

10.1.1. Chemotherapy

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Radiotherapy

10.1.2.1. Market Revenue and Forecast (2020-2032)

10.1.3. Immunotherapy

10.1.3.1. Market Revenue and Forecast (2020-2032)

10.1.4. Others

10.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Artificial Intelligence (AI) in Oncology Market, By End-Users 

11.1. Artificial Intelligence (AI) in Oncology Market, by End-Users, 2023-2032

11.1.1. Hospitals

11.1.1.1. Market Revenue and Forecast (2020-2032)

11.1.2. Diagnostic Centers

11.1.2.1. Market Revenue and Forecast (2020-2032)

11.1.3. Pharmaceutical Companies

11.1.3.1. Market Revenue and Forecast (2020-2032)

11.1.4. Research Institutes

11.1.4.1. Market Revenue and Forecast (2020-2032)

11.1.5. Others

11.1.5.1. Market Revenue and Forecast (2020-2032)

Chapter 12. Global Artificial Intelligence (AI) in Oncology Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Component (2020-2032)

12.1.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

12.1.3. Market Revenue and Forecast, by Treatment Type (2020-2032)

12.1.4. Market Revenue and Forecast, by End-Users (2020-2032)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Component (2020-2032)

12.1.5.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

12.1.5.3. Market Revenue and Forecast, by Treatment Type (2020-2032)

12.1.5.4. Market Revenue and Forecast, by End-Users (2020-2032)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Component (2020-2032)

12.1.6.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

12.1.6.3. Market Revenue and Forecast, by Treatment Type (2020-2032)

12.1.6.4. Market Revenue and Forecast, by End-Users (2020-2032)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Component (2020-2032)

12.2.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

12.2.3. Market Revenue and Forecast, by Treatment Type (2020-2032)

12.2.4. Market Revenue and Forecast, by End-Users (2020-2032)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Component (2020-2032)

12.2.5.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

12.2.5.3. Market Revenue and Forecast, by Treatment Type (2020-2032)

12.2.5.4. Market Revenue and Forecast, by End-Users (2020-2032)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Component (2020-2032)

12.2.6.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

12.2.6.3. Market Revenue and Forecast, by Treatment Type (2020-2032)

12.2.6.4. Market Revenue and Forecast, by End-Users (2020-2032)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Component (2020-2032)

12.2.7.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

12.2.7.3. Market Revenue and Forecast, by Treatment Type (2020-2032)

12.2.7.4. Market Revenue and Forecast, by End-Users (2020-2032)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Component (2020-2032)

12.2.8.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

12.2.8.3. Market Revenue and Forecast, by Treatment Type (2020-2032)

12.2.8.4. Market Revenue and Forecast, by End-Users (2020-2032)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Component (2020-2032)

12.3.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

12.3.3. Market Revenue and Forecast, by Treatment Type (2020-2032)

12.3.4. Market Revenue and Forecast, by End-Users (2020-2032)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Component (2020-2032)

12.3.5.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

12.3.5.3. Market Revenue and Forecast, by Treatment Type (2020-2032)

12.3.5.4. Market Revenue and Forecast, by End-Users (2020-2032)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Component (2020-2032)

12.3.6.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

12.3.6.3. Market Revenue and Forecast, by Treatment Type (2020-2032)

12.3.6.4. Market Revenue and Forecast, by End-Users (2020-2032)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Component (2020-2032)

12.3.7.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

12.3.7.3. Market Revenue and Forecast, by Treatment Type (2020-2032)

12.3.7.4. Market Revenue and Forecast, by End-Users (2020-2032)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Component (2020-2032)

12.3.8.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

12.3.8.3. Market Revenue and Forecast, by Treatment Type (2020-2032)

12.3.8.4. Market Revenue and Forecast, by End-Users (2020-2032)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Component (2020-2032)

12.4.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

12.4.3. Market Revenue and Forecast, by Treatment Type (2020-2032)

12.4.4. Market Revenue and Forecast, by End-Users (2020-2032)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Component (2020-2032)

12.4.5.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

12.4.5.3. Market Revenue and Forecast, by Treatment Type (2020-2032)

12.4.5.4. Market Revenue and Forecast, by End-Users (2020-2032)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Component (2020-2032)

12.4.6.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

12.4.6.3. Market Revenue and Forecast, by Treatment Type (2020-2032)

12.4.6.4. Market Revenue and Forecast, by End-Users (2020-2032)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Component (2020-2032)

12.4.7.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

12.4.7.3. Market Revenue and Forecast, by Treatment Type (2020-2032)

12.4.7.4. Market Revenue and Forecast, by End-Users (2020-2032)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Component (2020-2032)

12.4.8.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

12.4.8.3. Market Revenue and Forecast, by Treatment Type (2020-2032)

12.4.8.4. Market Revenue and Forecast, by End-Users (2020-2032)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Component (2020-2032)

12.5.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

12.5.3. Market Revenue and Forecast, by Treatment Type (2020-2032)

12.5.4. Market Revenue and Forecast, by End-Users (2020-2032)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Component (2020-2032)

12.5.5.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

12.5.5.3. Market Revenue and Forecast, by Treatment Type (2020-2032)

12.5.5.4. Market Revenue and Forecast, by End-Users (2020-2032)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Component (2020-2032)

12.5.6.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

12.5.6.3. Market Revenue and Forecast, by Treatment Type (2020-2032)

12.5.6.4. Market Revenue and Forecast, by End-Users (2020-2032)

Chapter 13. Company Profiles

13.1. IBM

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Azra AI

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Siemens Healthineers

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. GE Healthcare

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Intel

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Path AI

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. NVIDIA

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Concert.AI

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Digital Diagnostics Inc.

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Median Technologies

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Contact Us:

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 774 402 6168

Email: sales@precedenceresearch.com

Website: https://www.precedenceresearch.com

 Blog: https://www.pharma-geek.com

 

 

Tags:

Post a Comment

0 Comments